The regulatory role of AT1 receptor on activated HSCs in hepatic fibrogenesis: Effects of RAS inhibitors on hepatic fibrosis induced by CCl4

Table 1 Effects of RAS inhibitors on rat serum levels of ALT and AST

	n	ALT (U/L)	AST (U/L)
Control	10	99.50 ± 18.78	244.50 ± 46.52
Model	7	1863.29 ± 893.68a	2680.86 ± 1039.12a
Enalapril	7	466.14 ± 132.64b	785.29 ± 262.40b
Losartan	8	535.25 ± 200.78b	777.50 ± 270.32b
Enalapril+losartan	8	863.87 ± 345.75c	449.60 ± 130.36b

^aP < 0.01 vs comtrol;

^bP < 0.01 vs Model;

^cP < 0.05 vs Model.

Table 2 Serum renin activity and AngII levels

	n	Renin (μg·L-1/h)	AngII (ng/L)
Control	10	4.63 ± 2.87	495.78 ± 248.96
Model	7	17.70 ± 12.13a	1505.46 ± 849.72a
Enalapril	7	6.85 ± 4.59b	951.78 ± 451.67
Losartan	8	10.92 ± 4.97	747.62 ± 316.34b
Enalapril+losartan	8	7.84 ± 5.78	643.82 ± 261.47b

^aP < 0.01 vs Control;

^bP < 0.05 vs Model.

Table 3 Fibrosis measurements

	Control	Model	Enalapril	Losartan	Enalapril+losartan
Area of fibrosis	0.94 ± 0.33	11.22 ± 4.79a	5.38 ± 3.43b	4.96 ± 2.96b	4.23 ± 3.70b

^aP < 0.01 vs Control;

^bP < 0.05 vs Model.